#1 Clinical Trials Search in Europe

2-DEOXY-D-GLUCOSE

Clinical trials are studying 2-DEOXY-D-GLUCOSE in healthy adults to see whether it can help prevent rhinovirus-associated illness. These trials focus on how well it works compared with placebo, and they also look at safety and other study outcomes.

Table of contents

Trial overview

This article covers one clinical trial of 2-DEOXY-D-GLUCOSE in healthy adults with a focus on rhinovirus-associated illness.[1] The study title describes it as a controlled human rhinovirus infection study, and the brief summary says it was done to confirm whether 2-DEOXY-D-GLUCOSE worked better than placebo for prevention.[1]

The trial was Phase 2, which means it was designed to look more closely at whether the study treatment may work in a specific group of people.[1] It was also an interventional study, meaning the researchers gave a study treatment and compared the results with another group.[1]

Study design and treatment groups

The study compared 2-DEOXY-D-GLUCOSE with placebo.[1] A placebo is a look-alike treatment with no active study drug, used so results can be compared fairly.[1]

The intervention list shows a placebo group and a 2-DEOXY-D-GLUCOSE group given as a nasal spray at 56 mg.[1] The trial was completed and enrolled 128 people.[1]

Who participated

The study enrolled healthy adults.[1] In clinical trials, healthy adults are often chosen when the goal is to test prevention, because they do not already have the target illness at the start of the study.[1]

The condition being studied was rhinovirus-associated illness, which is illness linked to rhinovirus infection.[1] This type of study helps researchers observe whether the treatment can reduce the chance of getting sick after controlled virus exposure.[1]

Main outcome measured

The primary outcome was the difference in the rate of rhinovirus-associated illness between 2-DG and placebo.[1] A primary outcome is the main result the researchers planned to measure to answer the study question.[1]

This outcome shows that the main aim was to find out whether 2-DEOXY-D-GLUCOSE could help prevent illness better than placebo in this study setting.[1]

What this trial adds

This completed Phase 2 trial adds early clinical evidence about 2-DEOXY-D-GLUCOSE for prevention of rhinovirus-associated illness in healthy adults.[1] Because the study was controlled and compared with placebo, it was set up to give a clearer answer about whether the treatment changed illness rates.[1]

The available trial data do not show results in this source, so the main information here is about the study question, the population, the phase, and the outcome being measured.[1]

Trial ID Phase Condition Studied Status Enrollment
2023-509311-91-01 Phase 2 Rhinovirus-associated illness Completed 128

FAQ

  • What is being studied in the 2-DEOXY-D-GLUCOSE trial? The trial is studying whether 2-DEOXY-D-GLUCOSE can lower the rate of rhinovirus-associated illness compared with placebo. The main goal is to test prevention in a controlled human rhinovirus infection study.
  • Who can take part in this trial? The study enrolled healthy adults. This means the trial looked at people without the illness at the start so researchers could measure prevention clearly.
  • What phase is the 2-DEOXY-D-GLUCOSE trial? This study is a Phase 2 trial. Phase 2 trials usually look more closely at whether a treatment works in a specific group of people.
  • What condition is this trial focused on? The trial focuses on rhinovirus-associated illness. Rhinovirus is a common cause of cold-like symptoms, and the study tested prevention of illness after controlled infection.
  • What outcome did the trial measure? The main outcome was the difference in the rate of rhinovirus-associated illness between 2-DEOXY-D-GLUCOSE and placebo. This helps show whether the study treatment changed how often illness happened.

Ongoing Clinical Trials on 2-DEOXY-D-GLUCOSE

  • Study on 2-Deoxy-D-Glucose for Preventing Common Cold in Healthy Adults

    Not recruiting

    1
    Investigated drugs:
    The Netherlands

Glossary

  • Rhinovirus: A common virus that can cause cold-like illness, such as runny nose, sore throat, and cough.
  • Rhinovirus-associated illness: Illness caused by rhinovirus infection. In this study, the focus was on whether the illness could be prevented.
  • Healthy adults: Adults without the target illness at the time of the study. They are often chosen so researchers can study prevention clearly.
  • Placebo: A look-alike treatment with no active study drug. It helps researchers compare results fairly.
  • Phase 2: A stage of clinical research that usually checks whether a treatment works in a chosen group and continues to look at safety.
  • Interventional study: A trial where researchers give a treatment or placebo and then measure the results.
  • Controlled human infection study: A study in which volunteers are exposed to a virus under careful medical supervision so researchers can measure the effect of a treatment.
  • Primary outcome: The main result the researchers planned to measure to answer the study question.
  • Enrollment: The number of people who joined the study.

References

  1. https://clinicaltrials.gov/study/2023-509311-91-01